Viralytics Ltd

43 articles about Viralytics Ltd

• 

  Boehringer Ingelheim Expands Oncolytic Virus Program and Buys ViraTherapeutic...

  9/13/2018

  Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.
• 

  More than $100 Billion Spent on M&A in the First 6 Months of 2018

  7/5/2018

  So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
• 

  Flurry of Activity: Top 2018 Biopharma M&A Deals So Far

  5/3/2018

  While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.

• Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline

  2/21/2018

  Merck and Viralytics Ltd today announced that the companies have signed a definitive agreement under which it is proposed that Merck, through a subsidiary, will acquire Viralytics...

• 

  Merck Drops $394 Million to Acquire Virus-Based Cancer Company Viralytics

  2/21/2018

  Merck is driving forward in its quest to develop a premier immuno-oncology pipeline by acquiring Australia-based Viralytics Limited and its oncolytic immunotherapy treatments.

• Lepu Medical Pays $23.3M for 13% Stake in Australia's Viralytics

  1/9/2018

  Viralytics will use the funds for an Australian Phase III trial of CAVATAK, its oncolytic immunotherapy based on a common cold virus.

• Viralytics Ltd Updates CAVATAK and KEYTRUDA Combination Clinical Trials At ESMO 2016

  10/10/2016

• Viralytics Ltd Release: CAVATAK YERVOY Combination Demonstrates Promising Clinical Response Rates In Advanced Melanoma

  10/10/2016

• Viralytics Ltd Release: Positive Clinical Data From CAVATAK And YERVOY Combination Presented At The 2016 AACR Annual Meeting

  4/19/2016

• Viralytics Ltd Release: CAVATAK Increases Anti-Cancer Immune Activity In The Tumor Micro-environment

  4/19/2016

• Combinations Of Viralytics Ltd CAVATAK And Checkpoint Immunotherapy Demonstrate Anti-Cancer Activity In Preclinical Lung Cancer And Melanoma Studies

  4/19/2016

• Viralytics Ltd Release: Positive CAVATAK Clinical Data Presented At 2016 European Association Of Urology Congress

  3/15/2016

• Viralytics Ltd Completes $28 Million Placement -- SPP To Follow

  12/14/2015

• Viralytics Ltd Completes $28 Million Placement -- SPP To Follow

  12/14/2015

• Viralytics Ltd Release: Positive CAVATAKTM Clinical Data Presented At 2015 Society For Immunotherapy Of Cancer (SITC) Meeting

  11/9/2015

• Viralytics Ltd And Merck & Co., Kenilworth, New Jersey, U.S.A. To Collaborate On Combination Clinical Trial Of CAVATAK And KEYTRUDA In Lung And Bladder Cancer

  11/6/2015

• Viralytics Ltd Presents Phase 2 Melanoma Extension Cohort Data, Updated CALM Study Survival And CAVATAK/Immune Checkpoint Combination Preclinical Data At 2015 European Cancer Congress

  9/28/2015

• Viralytics Ltd Initiates Clinical Trial Of CAVATAK In Combination With PD-1 Blocker Keytruda

  9/28/2015

• Viralytics Ltd Presents CALM And STORM Clinical Trial Results At Oncolytic Virus Therapeutics Conference

  6/17/2015

• Viralytics Ltd Release; CAVATAK Presentations At Oncolytic Virus Therapeutics Conference Reinforce Potential In Bladder Cancer And Melanoma

  6/16/2015